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2714previously read, “Enoxaparin: 1 mg/kg subcutaneous (SC) every 12 hours (reduce dose to 1 mg/kg SC once
daily in patients with creatinine clearance [CrCl] <30 mL/min), continued for the duration of hospitali-
zation or until PCI is performed. An initial intravenous loading dose is 30 mg (133,136,309).”
9. Section 4.3.2.1, paragraph 1, line 6. The text now reads, “The dose of enoxaparin is 1 mg/kg SC every
12 hours for NSTE-ACS; an initial intravenous loading dose of 30 mg has been used in selected patients.”
The text previously read, “The dose of enoxaparin is 1 mg/kg SC every 12 hours for NSTE-ACS; an initial
intravenous loading dose is 30 mg.”
10. Section 6.2.1, Class IIa, Recommendation #2. The recommendation now reads, “It is reasonable to use
ticagrelor in preference to clopidogrel for maintenance-P2Y12 treatment in patients with NSTE-ACS who
undergo an early invasive or ischemia-guided strategy (293, 294).” The recommendation previously read,
“It is reasonable to choose ticagrelor over clopidogrel for maintenance P2Y12 treatment in patients with
NSTE-ACS treated with an early invasive strategy and/or PCI (293, 294).”http://dx.doi.org/10.1016/j.jacc.2014.10.011CORRECTION
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1. Cover page. The collaborating organizations title line now reads, “Developed in Collaboration With the
Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons”. The text
previously read, “Developed in Collaboration With the Society of Thoracic Surgeons”.
2. Section 3.3, Figure 2(A). GRACE Risk Model Nomogram, footnote list. The footnote now reads, “To convert
serum creatinine level to micromoles per liter, multiply by 88.4.” The footnote previously read, “To convert
serum creatine level to micromoles per liter, multiply by 88.4.”
3. Section 4.2, Class I, Recommendation #3. The recommendation now refers to “or hyperkalemia
(Kþ >5.0 mEq/L)”. The recommendation previously referred to “hyperkalemia (K >5.0mEq/L)”.
4. Section 4.3.1, Class I, Recommendation #1. The maintenance dose for aspirin has been changed. Addition-
ally, the following references, numbered 147 and 363, have been added to the text: 147. Wallentin L, Becker
RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med.
2009;361:1045-57; and 363. Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose
clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary
intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomized factorial trial. Lancet.
2010;376:1233-43. The recommendation now reads, “and a maintenance dose of aspirin (81 mg/d to 325
mg/d) should be continued indeﬁnitely (142–144,147,363).” The recommendation previously read “and a
maintenance dose of aspirin (81 mg/d to 162 mg/d) should be continued indeﬁnitely (142-144).”
5. Section 4.3.1, Table 7, row 3, column 5. The references now read, “(142-144)”. The references previously
read, “142-144, 147, 363”.
6. Section 4.3.1, Table 7, row 4, column 2. Text regarding aspirin maintenance dosing has been modiﬁed.
Additionally, the following references, numbered 147 and 363, have been added to column 5: 147. Wallentin
L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
N Engl J Med. 2009;361:1045-57; and 363. Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose
versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing
percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomized
factorial trial. Lancet. 2010;376:1233-43. The table now reads, “81 mg/d-325 mg/d*”. The asterisk (*) inserted
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2715after “325 mg/d” refers to the accompanying footnote below Table 7, which reads, “The recommended
maintenance dose of aspirin to be used with ticagrelor is 81 mg daily (144).” The table previously read,
“81 mg/d-162 mg/d”.
7. Section 4.3.1, Table 7, row 13, column 2. The bullet now reads, “Initial 30 mg IV loading dose in selected
patients”. The bullet previously read, “Initial IV loading dose 30 mg”.
8. Section 4.3.2, Class I, Recommendation #1. The recommendation now reads, “Enoxaparin: 1 mg/kg subcu-
taneous (SC) every 12 hours (reduce dose to 1 mg/kg SC once daily in patients with creatinine clearance
[CrCl] <30 mL/min), continued for the duration of hospitalization or until PCI is performed. An initial
intravenous loading dose of 30 mg has been used in selected patients (151-153).” The recommendation
previously read, “Enoxaparin: 1 mg/kg subcutaneous (SC) every 12 hours (reduce dose to 1 mg/kg SC once
daily in patients with creatinine clearance [CrCl] <30 mL/min), continued for the duration of hospitalization
or until PCI is performed. An initial intravenous loading dose is 30 mg (151-153).”
9. Section 6.2, Class IIa, Recommendation #2. The recommendation now reads, “It is reasonable to use
ticagrelor in preference to clopidogrel for maintenance-P2Y12 treatment in patients with NSTE-ACS who
undergo an early invasive or ischemia-guided strategy (147,148).” The recommendation previously read, “It
is reasonable to choose ticagrelor over clopidogrel for maintenance P2Y12 treatment in patients with
NSTE-ACS treated with an early invasive strategy and/or PCI (147,148).”http://dx.doi.org/10.1016/j.jacc.2014.11.021
